Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 10:10 AM ET on Jan 30, 2015
Last Price Change Open Day High 52-Week High
1.30  down   (2.719%) 47.89 48.96 49.70
Volume Previous Close Day Low 52-Week Low
28,400 47.81 46.41 12.75

View all »   RSSRecent Releases

Jan 5, 2015
Esperion Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference

Nov 12, 2014
Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference